Prosecution Insights
Prosecution Insights
9 pending office actions • 8 clients • 9 examiners • 8 art units • 0 of 9 (0%) have an AI response strategy ready • 27 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (33%) |
| §112 only | 1 (11%) |
| Double-patenting + other | 1 (11%) |
| No statute on record | 4 (44%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PHAN, DOAN THI-THUC | 1 | 42.7% | +49.8% |
| BOWERS, ERIN M | 1 | 54.9% | +11.4% |
| ARNOLD, ERNST V | 1 | 48.0% | +12.9% |
| MARTIN, RACHEL E | 1 | 53.1% | +57.2% |
| FULTON, MICHAEL TIMOTHY | 1 | 69.6% | +5.6% |
| SCHMIDT, IZABELA MARIA | 1 | 63.1% | +53.5% |
| HELM, CARALYNNE E | 1 | 28.8% | +49.6% |
| CHONG, KIMBERLY | 1 | 72.4% | +12.7% |
| NOLAN, JASON MICHAEL | 1 | 65.7% | -28.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042970 | Methods and Uses of Producing Compositions Stably Comprising Free Available Chlorine Species and Peroxides | HELM, CARALYNNE E | 79d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042970 | Methods and Uses of Producing Compositions Stably Comprising Free Available Chlorine Species and Peroxides | HELM, CARALYNNE E | 79d overdue |
| 18072674 | Method of purifying mRNA using substrate dependent ribozyme and solid-support attachment tag | CHONG, KIMBERLY | 43d overdue |
| 18392498 | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration | MARTIN, RACHEL E | 29d overdue |
| 18626760 | COSMETIC EMULSION BASES (CEB) | PHAN, DOAN THI-THUC | 16d overdue |
| 18693468 | Reducing or Inhibiting Tissue Damage Using Hyaluronidase Administration | BOWERS, ERIN M | 3d overdue |
| 18192624 | Anti-Oncogenic Phytochemicals and Methods and Uses for Treating Cancer | SCHMIDT, IZABELA MARIA | 21d |
| 18595716 | Solid Solution Compositions and Use in Severe Pain | ARNOLD, ERNST V | 61d |
| Client (Assignee) | Pending OAs |
|---|---|
| Med Progress, LLC | 2 |
| Suncoast Products LLC | 1 |
| Infirst Healthcare Limited | 1 |
| INFLOWVENT LTD. | 1 |
| Ostentus Therapeutics, Inc. | 1 |
| Collidion | 1 |
| Cisterna Biologics, Inc. | 1 |
| Irvine Labs, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 1613 | 2 |
| 1653 | 1 |
| 1657 | 1 |
| 1747 | 1 |
| 1621 | 1 |
| 1615 | 1 |
| 1636 | 1 |
| 1623 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18626760 | COSMETIC EMULSION BASES (CEB) | Suncoast Products, LLC | PHAN, DOAN THI-THUC | 1613 | Other | Non-Final OA | 16d overdue | Pending | Apr 04, 2024 |
| 18693468 | Reducing or Inhibiting Tissue Damage Using Hyaluronidase Administration | Med Progress, LLC | BOWERS, ERIN M | 1653 | Other | Non-Final OA | 3d overdue | Pending | Mar 19, 2024 |
| 18595716 | Solid Solution Compositions and Use in Severe Pain | Infirst Healthcare Limited | ARNOLD, ERNST V | 1613 | DPOther | Non-Final OA | 61d | Pending | Mar 05, 2024 |
| 18392498 | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration | Med Progress, LLC | MARTIN, RACHEL E | 1657 | Other | Non-Final OA | 29d overdue | Pending | Dec 21, 2023 |
| 18031109 | A DEVICE AND A METHOD FOR VAPORISING A VOLATILE MATERIAL | Inflowvent Ltd. | FULTON, MICHAEL TIMOTHY | 1747 | §103 | Non-Final OA | 66d overdue | Pending | Apr 10, 2023 |
| 18192624 | Anti-Oncogenic Phytochemicals and Methods and Uses for Treating Cancer | Ostentus Therapeutics, Inc. | SCHMIDT, IZABELA MARIA | 1621 | Other | Non-Final OA | 21d | Pending | Mar 29, 2023 |
| 18042970 | Methods and Uses of Producing Compositions Stably Comprising Free Available Chlorine Species and Peroxides | Collidion, Inc. | HELM, CARALYNNE E | 1615 | §103 | Final Rejection | 79d overdue | Pending | Feb 24, 2023 |
| 18072674 | Method of purifying mRNA using substrate dependent ribozyme and solid-support attachment tag | Cisterna Biologics, Inc. | CHONG, KIMBERLY | 1636 | §112 | Final Rejection | 43d overdue | Pending | Nov 30, 2022 |
| 17191470 | Cannabis Treatment of Insomnia, Pain, and Skin Conditions | Irvine Labs, Inc. | NOLAN, JASON MICHAEL | 1623 | §103 | Final Rejection | 7d | Pending | Mar 03, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial